{"id":1429,"date":"2026-04-28T01:34:35","date_gmt":"2026-04-28T01:34:35","guid":{"rendered":"https:\/\/www.insilens.com\/?p=1429"},"modified":"2026-04-28T01:36:16","modified_gmt":"2026-04-28T01:36:16","slug":"cormedix-rezafungin-phase-3-hsct-prophylaxis","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=1429","title":{"rendered":"CorMedix \u2013 Rezafungin Phase 3 (HSCT Prophylaxis)"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Summary<\/h4>

CorMedix reported positive Phase 3 results from the ReSPECT trial for rezafungin (REZZAYO), demonstrating non-inferiority to standard antimicrobial regimens for prevention of invasive fungal disease (IFD) in allogeneic hematopoietic stem cell transplant (allo-HSCT) patients.<\/p>

What Happened<\/h4>

The Phase 3 ReSPECT study met its primary endpoint of fungal-free survival at Day 90, with rates of 60.7% for rezafungin versus 59.0% for standard of care.

Rezafungin also showed a favorable safety profile, including fewer toxicity-related discontinuations and fewer treatment-emergent adverse events leading to dose modification or withdrawal.

CorMedix plans a pre-NDA meeting and supplemental NDA submission in 2H 2026.<\/p>

Deep Analysis<\/h4>

This is a clinically relevant but moderate-strength signal. Non-inferiority confirms rezafungin as a viable alternative to existing prophylaxis, but not a breakthrough in efficacy.

The key differentiator is operational: once-weekly dosing versus daily regimens. In allo-HSCT patients\u2014who are highly immunocompromised and burdened by complex polypharmacy\u2014this is a meaningful advantage.

Reducing treatment complexity can improve adherence, reduce toxicity management burden, and potentially lower non-relapse mortality driven by invasive fungal infections.

From a strategic standpoint, this reinforces that supportive care innovations in transplant populations can be commercially significant even without superior efficacy.

However, as a supplemental indication rather than a novel mechanism, the upside is more incremental than transformative.<\/p>

Company \/ Product Background<\/h4>

CorMedix Therapeutics is a biopharmaceutical company focused on anti-infective therapies.

Allogeneic HSCT patients are at high risk for invasive fungal infections due to prolonged immunosuppression. These infections\u2014caused by pathogens such as Candida, Aspergillus, and Pneumocystis\u2014are a major contributor to non-relapse mortality.

Rezafungin is an echinocandin antifungal that inhibits fungal cell wall glucan synthesis. Its extended half-life enables once-weekly intravenous dosing, offering a differentiated administration profile.<\/p>

Signal Extraction<\/h4>

– Supportive care remains critical in transplant outcomes
– Non-inferiority + convenience can drive adoption
– Once-weekly dosing is key differentiation
– Large commercial opportunity despite incremental efficacy<\/p>

Insilens Take<\/h4>

– Opportunity: Improve HSCT supportive care workflows
– Threat: Limited differentiation on efficacy
– Watch Signal: sNDA acceptance and label expansion
– Action: Track antifungal strategies in transplant settings<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Summary CorMedix reported positive Phase 3 results from the ReSPECT trial for rezafungin (REZZAYO), demonstrating non-inferiority to standard antimicrobial regimens for prevention of invasive fungal disease (IFD) in allogeneic hematopoietic stem cell transplant (allo-HSCT) patients. What Happened The Phase 3 ReSPECT study met its primary endpoint of fungal-free survival at Day 90, with rates of […]<\/p>\n","protected":false},"author":1,"featured_media":1424,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,3],"tags":[],"class_list":["post-1429","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-therapeutic-indication"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/1429","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1429"}],"version-history":[{"count":4,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/1429\/revisions"}],"predecessor-version":[{"id":1433,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/1429\/revisions\/1433"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/1424"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1429"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1429"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1429"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}